Pacira BioSciences to Acquire iovera° in Up to $140 Million Asset-Purchase Deal
The acquisition of the non-opioid pain-management device advances Pacira's pivot toward a broader biopharmaceutical platform under its 5x30 strategy.
Pacira BioSciences (PCRX) agreed to acquire the iovera° system in an asset-purchase transaction valued at up to $140 million, the company said. The deal calls for $70 million in cash paid at closing, with an additional $70 million in potential milestone payments tied to future revenue performance. Pacira expects the transaction to close in the third quarter of 2026.
The iovera° system is a handheld device that uses controlled cold therapy to temporarily block peripheral nerve signals, offering a non-opioid approach to acute and chronic pain management. The technology complements Pacira's existing portfolio of non-opioid analgesics, including its flagship Exparel liposomal bupivacaine injection, and extends the company's reach into device-based pain solutions.
Chief Executive Officer Frank D. Lee said the acquisition "advances our transition into an innovative biopharmaceutical company and aligns with our 5x30 strategy". Pacira has outlined that strategy as a roadmap to diversify beyond its legacy injectable franchise and build a broader platform spanning pharmaceuticals and medical devices.
The asset-purchase structure allows Pacira to acquire the iovera° technology and associated commercial rights without assuming legacy liabilities, a framework that keeps the upfront capital commitment at $70 million while preserving upside through the revenue-linked milestones. The contingent payments, capped at an additional $70 million, align the seller's economics with the product's commercial trajectory.
The deal arrives amid a wave of medtech and biopharma consolidation. Danaher Corporation's pending acquisition of Masimo Corporation for $180.00 a share in cash, which Masimo shareholders approved in May 2026, underscored large strategics' appetite for patient-monitoring and device platforms. Earlier, ARCA biopharma's reverse-merger combination with Oruka Therapeutics, backed by a $275 million private placement, illustrated the continued use of creative structures to fund pipeline-focused biopharma transactions.
Completion of the iovera° acquisition remains subject to customary closing conditions. Pacira has not disclosed expected accretion or integration costs, though the company has signaled that the asset would be folded into its existing commercial infrastructure for non-opioid pain therapies.